Fig. 3: KRASMut-induced SIRT1 rebinds to KRASMut and increases KRAS activity via deacetylation.
From: Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
A HEK293T cells were transfected with KRASG12C and SIRT1 plasmids (4 μg), and cell extracts were immunoprecipitated with anti-KRAS and anti-SIRT1 antibodies and immunoblotted with the reciprocal antibody. B, C Plasmids (pcDNA, KRASG12C, and SIRT1 each 4 μg) and siRNAs (siCon and siSIRT1, each 80 nM) were transfected into HEK293T cells. Cell extracts were immunoprecipitated with an anti-KRAS antibody and Raf-1 agarose beads and analyzed using anti-acetylated lysine, anti-SIRT1, anti-KRAS, and anti-KRAS-GTP antibodies. D Normal lung epithelial cell, fibroblast, and KRAS Mut cell lysates were immunoprecipitated with an anti-KRAS antibody and immunoblotted with anti-acetyl-lysine and anti-KRAS antibodies.
